KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Asset Utilization Ratio (2016 - 2025)

Historic Asset Utilization Ratio for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to 0.58.

  • Halozyme Therapeutics' Asset Utilization Ratio rose 2543.34% to 0.58 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.58, marking a year-over-year increase of 2543.34%. This contributed to the annual value of 0.53 for FY2024, which is 1528.04% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Asset Utilization Ratio of 0.58 as of Q3 2025, which was up 2543.34% from 0.55 recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Asset Utilization Ratio registered a high of 0.58 during Q3 2025, and its lowest value of 0.32 during Q3 2022.
  • Its 5-year average for Asset Utilization Ratio is 0.44, with a median of 0.43 in 2021.
  • As far as peak fluctuations go, Halozyme Therapeutics' Asset Utilization Ratio skyrocketed by 3788.12% in 2021, and later crashed by 2394.29% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Asset Utilization Ratio (Quarter) stood at 0.39 in 2021, then fell by 8.0% to 0.36 in 2022, then increased by 28.4% to 0.46 in 2023, then increased by 6.17% to 0.49 in 2024, then rose by 19.73% to 0.58 in 2025.
  • Its last three reported values are 0.58 in Q3 2025, 0.55 for Q2 2025, and 0.51 during Q1 2025.